Date:12/9/2010

boratory diagnostics services, Clarient's ability to obtain additional financing on acceptable terms or at all, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying, developing and commercializing new diagnostic tests or novel markers including the Mammostrat® test, Clarient's ability to fund development of new diagnostic tests and novel markers, and to obtain adequate patent protection covering Clarient's use of these tests and markers including for the Mammostrat® test, and the amount of resources Clarient determines to apply to novel marker development and commercialization, the risk to Clarient of infringement claims and the possibility of the need to license intellectual property from third parties to avoid or settle such claims, failure to obtain regulatory approvals and clearances required to conduct clinical trials if/when required and/or to commercialize Clarient's services and underlying diagnostic applications, Clarient's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in Clarient's SEC reports, including quarterly reports on Form 10-Q, current reports on Form 8-K, and annual reports on Form 10-K. Recent experience with respect to laboratory services, net revenues and results of operations may not be indicative of future results for the reasons set forth above.

Clarient does not assume any obligation to update any forward-looking statements or other information contained in this document.Investor ContactFor Clarient: Matt ClawsonAllen & Caron Inc(949) 474-4300matt@allencaron.com
'/>"/>

SOURCE Clarient, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.
2. Clarient Acquires Applied Genomics, Inc.
3. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
4. Clarient Announces CFO Transition Plan
5. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
6. CareFusion Launches Respiratory Airway Adapter to Improve Patient Safety and Reduce Hospital Costs
7. UBM TechInsights Launches Product Teardowns for Medical Electronics
8. Purdue Pharma L.P. Re-launches Partners Against Pain Website
9. CareFusion Launches Next-Generation Clinical Pulmonary and Cardiopulmonary Diagnostics Software
10. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
11. The Citizen CPR Foundation Launches National Call to Action to Empower Citizens to Save Lives of Those with Sudden Cardiac Arrest